So all the above has to happen to get a mid point valuation of 91c !!!We foresee the stock being re-rated to our valuation range if the following factors eventuate:
– Successful results from the PAR_OA_002 and PAR_OA_003 clinical trials.
– Regulatory approval, in both Australia and the USA,
– Commercial partnerships, either before or after regulatory approval, including potential licensing deals or even potential M&A, and
– Progress against other indications, particularly MPS.
Is that really the best we can hope for 91c after regulatory approval in USA & AU ?
Surely not
Ann: PAR RECEIVES POSITIVE RESPONSE FROM US FDA FOR PHASE 3, page-485
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
26.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $92.81M | |||
| Open | High | Low | Value | Volume |
| 27.0¢ | 29.0¢ | 25.5¢ | $430.3K | 1.585M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5500 | 26.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 26.5¢ | 36162 | 3 |
View Market Depth
| Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
| PAR (ASX) Chart |